Kalaris Therapeutics, Inc. (KLRS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Kalaris Therapeutics, Inc. (KLRS) closed at USD 2.13 on 2026-10-14, a change of -57.4 % over the past year, with a market capitalization of USD 52.13M.

Kalaris Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Kalaris Therapeutics, Inc. key figures

Previous close

USD 2.13 (2026-10-14)

1-year change

-57.4 %

Market cap

USD 52.13M

Enterprise value

USD -40.01M

P/E ratio (trailing)

-1.12

P/E ratio (forward)

-1.33

EPS (trailing)

-1.95

EPS (forward)

-1.65

PEG ratio

n/a

Price to book

0.90

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.93

Employees

20

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Kalaris Therapeutics, Inc. and compare it with other stocks.